Article

Modeling adaptive therapy in non-muscle invasive bladder cancer

2019-11-06

Abstract excerpt

Bladder cancer is the 9 th most commonly diagnosed cancer. Nearly half of patients with early stage bladder cancer treated with the immune-stimulating agent BCG have disease recurrence, while 13% progress to invasive bladder cancer. Here we explored the potential of tumor mutational heterogeneity and the role of pro- and anti-inflammatory cytokines to identify different subtypes of bladder cancer that may predict...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9baba2ac-d5d9-5f9f-a396-2392b1b4736c
DOI: 10.1101/826438

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Modeling adaptive therapy in non-muscle invasive bladder cancerDOI 10.1101/826438Read

Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studiesSemantic proximity Read

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohortsSemantic proximity Read

Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic AdvancesSemantic proximity Read

A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder CancerSemantic proximity Read

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infectionsSemantic proximity Read

Simulation Models for Bladder Cancer: A Scoping ReviewSemantic proximity Read

Serial Assessment of Circulating T lymphocyte Phenotype and Receptor Repertoire During Treatment of Non-Muscle Invasive Bladder Cancer with Adoptive T Cell ImmunotherapySemantic proximity Read

Reparameterized Multiobjective Control of BCG ImmunotherapySemantic proximity Read

Targeting CXCR4-expressing TAMs in muscle-invasive bladder cancer to enhance tumor control after immunotherapySemantic proximity Read

Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.Semantic proximity Read

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.Semantic proximity Read

Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patientsSemantic proximity Read